Clinician perspectives on the clinical utility of Belay Summit™ 2.0 cerebrospinal fluid test - A mixed methods study.
A spinal fluid cancer test identified genetic clues in 74% of brain tumor cases, helping clinicians confirm or rule out diagnoses more confidently.
This mixed-methods study at Johns Hopkins surveyed clinicians on the clinical utility of the Summit 2.0 CSF-based liquid biopsy NGS assay for CNS tumors (n=49 cases, 52% response rate). The assay demonstrated 74% positive genomic yield and clinician-reported utility in 86% of cases, including cases with negative results useful for ruling out diagnoses — though multiple authors are employed by or have equity in Belay Diagnostics.
What the study was
- Study design
- Mixed-methods clinician survey (prospective post-test utility assessment)
- Population
- Clinicians ordering CSF-based NGS testing for CNS tumor patients (n=49 surveyed cases)
- Sample size
- 49
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- The Journal of Liquid Biopsy
Why it surfaced
CSF liquid biopsy for CNS tumors addresses a genuine unmet need; clinician-utility data is relevant though limited by small n and significant COI (manufacturer study). NCCN already recommends NGS for CNS tumors.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.